Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
26
02
2024
accepted:
19
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
epublish
Résumé
The COVID-19 pandemic posed a challenge for people living with HIV (PLWH), particularly immune non-responders (INR) with compromised CD4 T-cell reconstitution following antiretroviral therapy (CD4 count <350 cells per mm
Identifiants
pubmed: 39384763
doi: 10.1038/s41541-024-00972-3
pii: 10.1038/s41541-024-00972-3
doi:
Types de publication
Journal Article
Langues
eng
Pagination
185Informations de copyright
© 2024. The Author(s).
Références
Abrams, E. M. & Szefler, S. J. COVID-19 and the impact of social determinants of health. Lancet Respir. Med. 8, 659–661 (2020).
pubmed: 32437646
pmcid: 7234789
doi: 10.1016/S2213-2600(20)30234-4
Cavanna, L., Citterio, C. & Toscani, I. COVID-19 vaccines in cancer patients. Seropositivity and safety. Systematic review and meta-analysis. Vaccines 9, https://doi.org/10.3390/vaccines9091048 (2021).
Galmiche, S. et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin. Microbiol. Infect. 28, 163–177 (2022).
pubmed: 35020589
doi: 10.1016/j.cmi.2021.09.036
Gao, Y., Chen, Y., Liu, M., Shi, S. & Tian, J. Impacts of immunosuppression and immunodeficiency on COVID-19: a systematic review and meta-analysis. J. Infect. 81, e93–e95 (2020).
pubmed: 32502509
pmcid: 7264926
doi: 10.1016/j.jinf.2020.05.017
Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. J. Allergy Clin. Immunol. 145, 1309–1321 (2020).
pubmed: 32386655
pmcid: 7198995
doi: 10.1016/j.jaci.2020.03.017
Jedicke, N. et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. HIV Med. 23, 558–563 (2022).
pubmed: 34725907
doi: 10.1111/hiv.13202
Kared, H. et al. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine 97, 104833 (2023).
pubmed: 37844534
pmcid: 10585642
doi: 10.1016/j.ebiom.2023.104833
Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab. Sci. 59, 373–390 (2022).
pubmed: 35220860
doi: 10.1080/10408363.2022.2038539
Hoft, M. A., Burgers, W. A. & Riou, C. The immune response to SARS-CoV-2 in people with HIV. Cell Mol. Immunol. 21, 184–196 (2024).
pubmed: 37821620
doi: 10.1038/s41423-023-01087-w
Hanson, H. A., Kim, E. & Badowski, M. E. A systematic review: impact of SARS-CoV-2 infection on morbidity, mortality, and viral suppression in patients living with HIV. SN Compr. Clin. Med. 5, 144 (2023).
pubmed: 37214621
pmcid: 10183680
doi: 10.1007/s42399-023-01480-6
Engsig, F. N. et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin. Infect. Dis. 58, 1312–1321 (2014).
pubmed: 24457342
pmcid: 6276895
doi: 10.1093/cid/ciu038
Pacheco, Y. M. et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antivir. Res. 117, 69–74 (2015).
pubmed: 25766861
doi: 10.1016/j.antiviral.2015.03.002
Yan, L. et al. Cellular and molecular insights into incomplete immune recovery in HIV/AIDS patients. Front. Immunol. 14, 1152951 (2023).
pubmed: 37205108
pmcid: 10185893
doi: 10.3389/fimmu.2023.1152951
Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141–155 (2011).
pubmed: 21090961
pmcid: 3759035
doi: 10.1146/annurev-med-042909-093756
Moir, S. & Fauci, A. S. B-cell responses to HIV infection. Immunol. Rev. 275, 33–48 (2017).
pubmed: 28133792
pmcid: 5300048
doi: 10.1111/imr.12502
Dandachi, D. et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin. Infect. Dis. 73, e1964–e1972 (2021).
pubmed: 32905581
doi: 10.1093/cid/ciaa1339
Kassanjee, R. et al. COVID-19 among adults living with HIV: correlates of mortality among public sector healthcare users in Western Cape, South Africa. J. Int. AIDS Soc. 26, e26104 (2023).
pubmed: 37339333
pmcid: 10281639
doi: 10.1002/jia2.26104
Tesoriero, J. M. et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw. Open 4, e2037069 (2021).
pubmed: 33533933
pmcid: 7859843
doi: 10.1001/jamanetworkopen.2020.37069
Wit, F. et al. COVID-19 in people with HIV in the Netherlands. AIDS 37, 1671–1681 (2023).
pubmed: 37199566
doi: 10.1097/QAD.0000000000003597
Yang, X. et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV 8, e690–e700 (2021).
pubmed: 34655550
pmcid: 8514200
doi: 10.1016/S2352-3018(21)00239-3
Russell, C. D., Lone, N. I. & Baillie, J. K. Comorbidities, multimorbidity and COVID-19. Nat. Med. 29, 334–343 (2023).
pubmed: 36797482
doi: 10.1038/s41591-022-02156-9
Cossu, M. V. et al. Comorbidity burden and suboptimal immunological responses to coronavirus disease 2019 vaccination in people living with human immunodeficiency virus. J. Infect. Dis. 227, 733–735 (2023).
pubmed: 35796710
doi: 10.1093/infdis/jiac286
Verburgh, M. L. et al. Robust vaccine-induced as well as hybrid B- and T-Cell immunity across SARS-CoV-2 vaccine platforms in people with HIV. Microbiol. Spectr. 11, e0115523 (2023).
pubmed: 37166335
doi: 10.1128/spectrum.01155-23
El Chaer, F. & El Sahly, H. M. Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity. Am. J. Med. 132, 437–446 (2019).
pubmed: 30611828
doi: 10.1016/j.amjmed.2018.12.011
Remschmidt, C., Wichmann, O. & Harder, T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine 32, 5585–5592 (2014).
pubmed: 25131742
doi: 10.1016/j.vaccine.2014.07.101
Tortellini, E. et al. Immunogenicity and efficacy of vaccination in people living with human immunodeficiency virus. Viruses 15, https://doi.org/10.3390/v15091844 (2023).
Brenchley, J. M. & Douek, D. C. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1, 23–30 (2008).
pubmed: 19079157
pmcid: 2777614
doi: 10.1038/mi.2007.1
Zicari, S. et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses 11, https://doi.org/10.3390/v11030200 (2019).
Ciabattini, A. et al. Evidence of SARS-CoV-2-specific memory B cells six months after vaccination with the BNT162b2 mRNA vaccine. Front. Immunol. 12, 740708 (2021).
pubmed: 34650563
pmcid: 8505800
doi: 10.3389/fimmu.2021.740708
Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, abm0829 (2021).
pubmed: 34648302
pmcid: 9284784
doi: 10.1126/science.abm0829
Notarte, K. I. et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review. J. Med. Virol. 94, 2939–2961 (2022).
pubmed: 35229324
pmcid: 9088566
doi: 10.1002/jmv.27688
Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26, 1636–1643 (2020).
pubmed: 32839624
pmcid: 7869028
doi: 10.1038/s41591-020-1051-9
Kared, H. et al. Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nat. Commun. 13, 4165 (2022).
pubmed: 35851055
pmcid: 9293966
doi: 10.1038/s41467-022-31888-y
Doni, A. et al. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Front. Immunol. 10, 712 (2019).
pubmed: 31019517
pmcid: 6459138
doi: 10.3389/fimmu.2019.00712
Garred, P. et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 349, 236–240 (1997).
pubmed: 9014910
doi: 10.1016/S0140-6736(96)08440-1
Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis. 29, 381–388 (2023).
pubmed: 36692375
pmcid: 9881762
doi: 10.3201/eid2902.221422
Coburn, S. B. et al. Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw. Open 5, e2215934 (2022).
pubmed: 35671054
pmcid: 9175076
doi: 10.1001/jamanetworkopen.2022.15934
Sun, J. et al. Association between immune dysfunction and COVID-19 breakthrough infection After SARS-CoV-2 vaccination in the US. JAMA Intern. Med. 182, 153–162 (2022).
pubmed: 34962505
doi: 10.1001/jamainternmed.2021.7024
Lane, H. C. et al. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309, 453–458 (1983).
pubmed: 6224088
doi: 10.1056/NEJM198308253090803
Zhou, Q. et al. Correlation between CD4 T-cell counts and seroconversion among COVID-19 vaccinated patients with HIV: a meta-analysis. Vaccines 11, https://doi.org/10.3390/vaccines11040789 (2023).
Tuan, J. J. et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. HIV Med. 23, 178–185 (2022).
pubmed: 34632695
doi: 10.1111/hiv.13188
Brockman, M. A. et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J. Infect. Dis. 225, 1129–1140 (2022).
pubmed: 34888688
doi: 10.1093/infdis/jiab592
Costiniuk, C. T. et al. COVID-19 vaccine immunogenicity in people with HIV. AIDS 37, F1–F10 (2023).
pubmed: 36476452
doi: 10.1097/QAD.0000000000003429
Heftdal, L. D. et al. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV - a prospective observational cohort study. EBioMedicine 93, 104661 (2023).
pubmed: 37331161
pmcid: 10272831
doi: 10.1016/j.ebiom.2023.104661
Levy, I. & Rahav, G. The effect of HIV on COVID-19 vaccine responses. Curr. Opin. HIV AIDS 18, 135–141 (2023).
pubmed: 36943427
doi: 10.1097/COH.0000000000000790
Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med 350, 1328–1337 (2004).
pubmed: 15044644
doi: 10.1056/NEJMra032015
Whitehurst, C. B. et al. HIV co-infection augments EBV-induced tumorigenesis in vivo. Front. Virol. 2, https://doi.org/10.3389/fviro.2022.861628 (2022).
Ho, J. et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc. Natl Acad. Sci. USA 103, 19436–19441 (2006).
pubmed: 17158796
pmcid: 1748244
doi: 10.1073/pnas.0609515103
Suryani, S. et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 115, 519–529 (2010).
pubmed: 19965666
doi: 10.1182/blood-2009-07-234799
Malaspina, A. et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc. Natl Acad. Sci. USA 103, 2262–2267 (2006).
pubmed: 16461915
pmcid: 1413756
doi: 10.1073/pnas.0511094103
Estes, J. D. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunol. Rev. 254, 65–77 (2013).
pubmed: 23772615
pmcid: 6066369
doi: 10.1111/imr.12070
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
pubmed: 34614326
doi: 10.1056/NEJMoa2114583
Perez-Alos, L. et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat. Commun. 13, 1614 (2022).
pubmed: 35347129
pmcid: 8960902
doi: 10.1038/s41467-022-29225-4
Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).
pubmed: 35016194
doi: 10.1038/s41586-021-04385-3
Karim, S. S. A. & Karim, Q. A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398, 2126–2128 (2021).
pubmed: 34871545
pmcid: 8640673
doi: 10.1016/S0140-6736(21)02758-6
Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).
pubmed: 35016198
doi: 10.1038/s41586-021-04388-0
Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119 (2021).
pubmed: 34488225
pmcid: 8566220
doi: 10.1038/s41586-021-03944-y
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
pubmed: 34237773
doi: 10.1038/s41586-021-03777-9
Vergori, A. et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat. Commun. 13, 4922 (2022).
pubmed: 35995780
pmcid: 9395398
doi: 10.1038/s41467-022-32263-7
Vergori, A. et al. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV. Int. J. Infect. Dis. 134, 195–199 (2023).
pubmed: 37343783
doi: 10.1016/j.ijid.2023.06.010
Alrubayyi, A. et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat. Commun. 12, 5839 (2021).
pubmed: 34611163
pmcid: 8492866
doi: 10.1038/s41467-021-26137-7
Donadeu, L. et al. Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV. AIDS 36, 1373–1382 (2022).
pubmed: 35730384
doi: 10.1097/QAD.0000000000003276
Peluso, M. J. et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS 36, F7–F16 (2022).
pubmed: 35866847
doi: 10.1097/QAD.0000000000003338
Riou, C. et al. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J. Clin. Invest. 131, https://doi.org/10.1172/JCI149125 (2021).
Feng, Y. et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine 43, 101226 (2022).
pubmed: 34901799
doi: 10.1016/j.eclinm.2021.101226
Frater, J. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV 8, e474–e485 (2021).
pubmed: 34153264
pmcid: 8213361
doi: 10.1016/S2352-3018(21)00103-X
Huang, X. et al. Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-negative individuals: a cross-sectional study in China. Viruses 14, https://doi.org/10.3390/v14020277 (2022).
Oyaert, M. et al. Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients. Front. Immunol. 13, 858399 (2022).
pubmed: 35401575
pmcid: 8988283
doi: 10.3389/fimmu.2022.858399
Woldemeskel, B. A. et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human Immunodeficiency Virus (HIV). Clin. Infect. Dis. 74, 1268–1270 (2022).
pubmed: 34293114
doi: 10.1093/cid/ciab648
Antinori, A. et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count. Clin. Infect. Dis. 75, e552–e563 (2022).
pubmed: 35366316
pmcid: 9047161
doi: 10.1093/cid/ciac238
Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488–492 (2022).
pubmed: 35102311
pmcid: 8930768
doi: 10.1038/s41586-022-04460-3
Redd, A. D. et al. Minimal crossover between mutations associated with Omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals. mBio 13, e0361721 (2022).
pubmed: 35229637
doi: 10.1128/mbio.03617-21
Redd, A. D. et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect. Dis. 8, ofab143 (2021).
pubmed: 34322559
pmcid: 8083629
doi: 10.1093/ofid/ofab143
Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847–859.e811 (2022).
pubmed: 35139340
pmcid: 8784649
doi: 10.1016/j.cell.2022.01.015
Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186–193 (2022).
pubmed: 35105982
doi: 10.1038/s41590-021-01122-w
Mallajosyula, V. et al. CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 6, https://doi.org/10.1126/sciimmunol.abg5669 (2021).
Peng, Y. et al. An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 23, 50–61 (2022).
pubmed: 34853448
doi: 10.1038/s41590-021-01084-z
Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell 185, 1041–1051.e1046 (2022).
pubmed: 35202566
pmcid: 8810349
doi: 10.1016/j.cell.2022.01.029
Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med. 386, 492–494 (2022).
pubmed: 34965337
doi: 10.1056/NEJMc2119358
Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351–355 (2022).
pubmed: 35584773
pmcid: 9279157
doi: 10.1038/s41586-022-04865-0
Agrati, C. et al. Persistent spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. Sci. Rep. 12, 6687 (2022).
pubmed: 35461335
pmcid: 9034067
doi: 10.1038/s41598-022-07741-z
Gao, F. et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8(+) T cell responses post SARS-CoV-2 infection. Immunity 56, 864–878.e864 (2023).
pubmed: 36996809
pmcid: 10017386
doi: 10.1016/j.immuni.2023.03.005
Korencak, M. et al. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight 4, https://doi.org/10.1172/jci.insight.126675 (2019).
Maslo, C. et al. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves. JAMA 327, 583–584 (2022).
pubmed: 34967859
doi: 10.1001/jama.2021.24868
Zhang, L. et al. Characterizing distinct profiles of immune and inflammatory response with age to Omicron infection. Front. Immunol. 14, 1189482 (2023).
pubmed: 37457688
pmcid: 10348361
doi: 10.3389/fimmu.2023.1189482
Campbell, J. H., Hearps, A. C., Martin, G. E., Williams, K. C. & Crowe, S. M. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 28, 2175–2187 (2014).
pubmed: 25144219
doi: 10.1097/QAD.0000000000000408
Msomi, N., Lessells, R., Mlisana, K. & de Oliveira, T. Africa: tackle HIV and COVID-19 together. Nature 600, 33–36 (2021).
pubmed: 34853449
doi: 10.1038/d41586-021-03546-8
Karim, F. et al. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nat. Commun. 15, 2360 (2024).
pubmed: 38491050
pmcid: 10943233
doi: 10.1038/s41467-024-46673-2
Peluso, M. J., Bakkour, S., Busch, M. P., Deeks, S. G. & Henrich, T. J. A high percentage of people with human immunodeficiency virus (HIV) on antiretroviral therapy experience detectable low-level plasma HIV-1 RNA following coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 73, e2845–e2846 (2021).
pubmed: 33211091
doi: 10.1093/cid/ciaa1754
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315, 801–810 (2016).
pubmed: 26903338
pmcid: 4968574
doi: 10.1001/jama.2016.0287
Holter, J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl Acad. Sci. USA 117, 25018–25025 (2020).
pubmed: 32943538
pmcid: 7547220
doi: 10.1073/pnas.2010540117
Jyssum, I. et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol. 4, e177–e187 (2022).
pubmed: 34977602
doi: 10.1016/S2665-9913(21)00394-5
Sikorski, K. et al. A high-throughput pipeline for validation of antibodies. Nat. Methods 15, 909–912 (2018).
pubmed: 30377371
doi: 10.1038/s41592-018-0179-8
Wu, W. et al. Antibody array analysis with label-based detection and resolution of protein size. Mol. Cell Proteom. 8, 245–257 (2009).
doi: 10.1074/mcp.M800171-MCP200